A review of the cultivation and processing of cannabis (Cannabis sativaL.) for production of prescription medicines in the UK

摘要: The quality demands of the pharmaceutical industry require prescription medicines to be consistent in their active ingredient content. Achieving this, using raw cannabis as a feedstock, is especially challenging. plant material extremely inhomogeneous, and ratios ingredients are affected by range factors. These include genetics plant, growing storage conditions, state maturity at harvest, methods used process formulate material. reasons for this variability described, with particular emphasis on botanical considerations. To produce complex medicine Sativex®, which contains cannabinoids Δ(9)-tetrahydrocannabinol (THC) cannabidiol (CBD) other ingredients, GW Pharmaceuticals had manage these variables. This medicine, treatment spasticity due multiple sclerosis, first cannabis-based approved UK. company's methodology producing chemotypes described.